Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update

OBJECTIVE: Treatment of dyslipidemia lowers cardiovascular (CV) risk. Although statin use is a cornerstone therapy, many patients are not achieving their risk-specific low-density lipoprotein cholesterol (LDL-C) goals. The proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies h...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Drug Assess
Autores principales: Kaddoura, Rasha, Orabi, Bassant, Salam, Amar M.
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2020
Materias:
Cardiovascular Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7470150/
https://ncbi.nlm.nih.gov/pubmed/32939318
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2020.1801452
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares